Supplementary material

Transcription

1 Supplementary material Comprehensive Characterization and Evaluation for Hepatocellular Carcinoma by LC-MS based Serum Metabolomics Journal: Metabolomics Xin Lu 1,3, Huan Nie 1, Yiqun Li 1, Chao Zhan 2, Xia Liu 1, Xiuyun Shi 1,3, Ming Shi 1, Yubao Zhang* 2 and Yu Li* 1,3 1 School of Life Science and Technology, Harbin Institute of Technology, Harbin, China 2 The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China 3 State Key Laboratory of Urban Water Resource and Environment, School of Life Science and Technology, Harbin Institute of Technology, Harbin, China. *Corresponding author: Yu Li, MD/Ph.D., professor Tel/Fax: liyugene@hit.edu.cn ; Address: Room 310, Building 2E, Science Park of Harbin Institute of Technology, No. 2 Yikuang Street, Nangang District, Harbin , China. *Corresponding author: Yubao Zhang, Tel/Fax: zhyb88077@sina.com Address: The Affiliated Tumor Hospital, Harbin Medical University, No. 150, Haping Road, Nangang District, Harbin , China.

2 Fig. S1 The typical UPLC/Q-TOF MS chromatograms for HCC, HBV and NC group in both positive ion mode (a, b and c for HCC, HBV and NC, respectively) and negative mode (d, e and f for HCC, HBV and NC, respectively)

3

4 Fig. S2 Extract ion chromatography, MS spectra and MS/MS spectra of differential metabolites (up-blank) and correspondent standard compounds (down-red) (a) D- Galactose. (b) L-Tryptophan. (c) 3-Indolelactic acid. (d) LyPC(16:0). (e) L-Glutamine. (f) Taurine. (g) Kynurenine (h) Succinic acid

5 Fig. S3 Box plots for comparing concentration levels of the three discriminative metabolites in different pathological stages and operative conditions. (a) Box plots from normal controls to HCC patients of different stages. (b) Box plots between paired preoperative HCC samples (Pre) and postoperative HCC samples (Post) * p< 0.05 ** p<

6 Table S1 Summary of the differentially expressed metabolites in HCC patients relative to non-hcc control subjects ID Category Marker Database ID Measured (m/z) Retention time(min) Formula Ion mode Trend 1 Sac_1 D-galactose a HMDB C 6 H 12 O 6 ** 2 Sac_2 1-[(5-Amino-5-carboxypentyl)amino]-1- deoxyfructose e C 12 H 24 N 2 O 7 M+FA-H ** 3 AA_1 L-Tryptophan a HMDB C 11 H 12 N 2 O 2 4 AA_2 L-Glutamine a HMDB C 5 H 10 N 2 O 3 5 AA_3 L-Phenylalamine a HMDB C 9 H 11 NO 2 6 AA_4 L-Threonine a HMDB C 4 H 9 NO 3 7 AA_5 L-Tyrosine a HMDB C 9 H 11 NO 3 8 AA_7 L-Lysine a HMDB C 6 H 14 N 2 O 2 9 AA_8 L-Serine a HMDB C 3 H 7 NO 3 10 AA_9 L-Leucine a HMDB C 6 H 13 NO 2 11 AA_10 L-Histidine a HMDB C 6 H 9 N 3 O 2 ** 12 AA_11 L-Methionine a HMDB C 5 H 11 NO 2 S ** 13 AA_12 L-Aspartic acid a HMDB C 4 H 7 NO 4 * 14 AA_13 L-Arginine a HMDB C 6 H 14 N 4 O 2 15 AA_14 DL-Kynurenine a HMDB C 10 H 12 N 2 O 3

7 16 AA_15 L-Glutamate a HMDB C 5 H 9 NO 4 ** 17 DP_1 L-Tryptophyl-L-Phenylalanine a HMDB C 20 H 21 N 3 O 3 18 DP_2 L-(Iso)leucyl-L-Phenylalanine a HMDB C 15 H 22 N 2 O 3 19 DP_3 L-Histidinyl-Cysteine a HMDB C 9 H 14 N 4 O 3 S DP_4 DP_5 S-Prenyl-Cysteine a L-Aspartyl-L-Phenylalanine a HMDB12286 HMDB C 8 H 15 NO 2 S C 13 H 16 N 2 O 5 22 DP_6 L-Phenylalanyl-L-Phenylalanine a HMDB C 18 H 20 N 2 O 3 23 DP_7 L-Glycyl-L-Glutamine a HMDB C 7 H 13 N 3 O 4 24 DP_8 L-Glycyl-L-Phenylalanine a HMDB C 11 H 14 N 2 O 3 25 DP_9 L-Glutamyl-L-Glutamate a HMDB C 10 H 14 N 2 O 7 ** 26 OA_1 Succinic acid a HMDB C 4 H 6 O 4 ** 27 OA_2 Citric acid a HMDB C 6 H 8 O 7 ** 28 OA_3 Taurine a HMDB C 2 H 7 NO 3 S ** 29 OA_4 Indoxylsulfuric acid a HMDB C 8 H 7 NO 4 S 30 OA_5 3-Indolelactic acid a HMDB C 10 H 9 O M+FA-H ST_1 ST_2 Taurocholate a Taurochenodeoxycholate a HMDB00036 HMDB C 26 H 45 NO 7 S C 26 H 45 NO 6 S ** ** 33 ST_3 Glycocholate a HMDB C 26 H 43 NO 6 * 34 ST_4 Glycochenodeoxycholate a HMDB C 32 H 51 NO 11 * 35 ST_5 3α,7α-Dihydroxy-5beta-cholestan-26-al b C C 26 H 42 O 4 M+FA-H *

8 36 ST_6 3-β-Hydroxyandrost-5-en-17-one sulfate c C 19 H 28 O 5 S 37 ST_7 7α-Hydroxycholest-4-en-3-one c C 27 H 44 O 2 M+FA-H 38 ST_8 Chenodeoxycholate c C 24 H 40 O 4 39 LyPC_1 LysoPC(16:0) a HMDB C 24 H 50 NO 7 P LyPC_2 LyPC_3 LyPC_4 LyPC_5 LysoPC(18:0) a LysoPC(18:1(11Z)) a LysoPC(20:3(8Z,11Z,14Z)) a LysoPC(18:2(9Z,12Z)) a HMDB10384 HMDB10385 HMDB10394 HMDB C 26 H 54 NO 7 P C 26 H 52 NO 7 P C 28 H 52 NO 7 P C 26 H 50 NO 7 P M+FA-H 44 LyPC_6 LysoPC(20:4(8Z,11Z,14Z,17Z) a HMDB C 28 H 50 NO 7 P M+FA-H 45 LyPC_7 LysoPC(17:0) a HMDB C 25 H 52 NO 7 P M+FA-H 46 LyPC_8 LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) a HMDB C 30 H 50 NO 7 P M+FA-H 47 LyPC_9 LysoPC(P-16:0) a HMDB C 24 H 50 NO 6 P M+FA-H 48 LyPC_10 LysoPC(18:2(9Z,12Z)) a HMDB C 26 H 50 NO 7 P M+FA-H LyPE_1 LyPE_2 LyPE_3 PC_1 PC_2 PC_3 PC_4 LysoPE(18:2(9Z,12Z)/0:0) a LysoPE(0:0/18:0) a LysoPE(20:2(11Z,14Z)/0:0) a 1-Linoleoyl glycerophosphochline a PC(O-18:2(9Z,12Z)/12:0) d PC(15:0/0:0) d PC(P-18:0/0:0) d HMDB11507 HMDB11129 HMDB11513 HMDB C 23 H 44 NO 7 P C 23 H 48 NO 7 P C 25 H 48 NO 7 P C 26 H 50 NO 7 P C 28 H 54 NO 7 P C 23 H 48 NO 7 P C 26 H 54 NO 6 P *

9 56 PC_5 PC(16:0) d C 24 H 50 NO 7 P M+FA-H 57 PC_6 PC(O-16:0/2:0) d C 26 H 54 NO 7 P M+FA-H 58 PC_7 PC(16:1(9Z)/2:0) d C 26 H 50 NO 8 P M+FA-H 59 PE_1 PE(P-16:0/0:0) d C 21 H 44 NO 6 P 60 PE_2 PE(P-18:0/0:0) d C 23 H 48 NO 6 P 61 PE_3 PE(20:0/20:4(5Z,8Z,11Z,14Z)) d C 45 H 82 NO 8 P M+FA-H 62 PG_1 PG(P-16:0/15:1(9Z)) d C 37 H 71 O 9 P M+Na+H ** 63 FA_1 (10E)-9-Oxo-10-hexadecenoic acid e C 16 H 28 O 3 ** 64 FA_2 12-HEPE a HMDB C 20 H 30 O 3 65 FA_3 EPA c C 20 H 30 O 2 66 FA_4 Docosahexaenoic acid a HMDB C 22 H 32 O 2 * 67 FA_5 13(S)-HODE d C 18 H 32 O 3 68 FA_6 (±)5-HETE c C 20 H 32 O 3 69 FA_7 6-trans-LTB4 a HMDB C 20 H 32 O 4 70 FA_8 (±)4-HDoHE c C 22 H 32 O 3 71 FA_9 Arachidonic Acid c C 20 H 32 O 2 * 72 FA_10 9-Octadecenoic acid a HMDB C 18 H 33 FO 2 M+FA-H 73 FA_11 (R)-3-Hydroxy-hexadecanoic acid a HMDB C 16 H 32 O 3 ** 74 C4 Butyryl-L-carnitine c C 11 H 21 NO 4 75 C8 Octanoyl-L-carnitine c C 15 H 29 NO 4

10 76 C8:1 Octenoyl-L-carnitine c C 15 H 27 NO 4 ** 77 C9 Nonanoyl-L-carnitine c C 16 H 31 NO 4 78 C10 Decanoyl-L-carnitine c C 17 H 33 NO 4 79 C11 Undecanoyl-L-carnitine a HMDB C 18 H 35 NO 4 80 C12 Dodecanoyl-L-carnitine c C 19 H 37 NO 4 * 81 C12:1 Dodecenoyl-L-carnitine a HMDB C 19 H 35 NO 4 * 82 C14 Tetradecanoyl-L-carnitine a HMDB C 21 H 41 NO 4 * 83 C14:1 Tetradecenoyl-L-carnitine a HMDB C 21 H 39 NO 4 * 84 C16 Palmitoyl-L-carnitine a HMDB C 23 H 45 NO 4 * 85 C16:1 Hexadecenoyl-L-carnitine a HMDB C 23 H 43 NO 4 ** 86 C18 Stearoyl-L-carnitine a HMDB C 25 H 49 NO 4 ** 87 C18:1 Octadecenyl-L-carnitine a HMDB C 25 H 47 NO 4 ** 88 C18:2 Octadecadienyl-L-carnitine a HMDB C 25 H 45 NO 4 ** 89 NA_1 Uridine a HMDB C 9 H 12 N 2 O 6 M+FA-H ** * p< 0.05; ** p< , up-regulated in HCC patients; down-regulated in HCC patients Referred databases: a. HMDB, b. KEGG, c. ChEBI, d. METLIN, e. ChemSpider